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OBJECTIVES This study was designed to examine the effects of pimobendan in a murine model of viral
myocarditis in relation to proinflammatory cytokine production and nitric oxide (NO)
synthesis by inducible NO synthase (iNOS) in the heart.
BACKGROUND Pimobendan has been recently confirmed to improve both acute and chronic heart failure.
Since the modulation of myocardial necrosis and contractile dysfunction by various proin-
flammatory cytokines may be partially mediated by the production of nitric oxide, the effects
of pimobendan on the production of proinflammatory cytokines and NO were investigated in
an animal model of viral myocarditis involving heart failure.
METHODS DBA/2 mice were inoculated with the encephalomyocarditis virus. To observe its effect on
survival up to 14 days, pimobendan (0.1 mg/kg or 1 mg/kg) or vehicles were given from the
day of virus inoculation (day 0) orally once daily. The effects of pimobendan on histological
changes, cytokine production, NO production and iNOS gene expression in the heart were
studied in mice treated either with pimobendan, 1 mg/kg or with vehicles only, and sacrificed
seven days after virus inoculation.
RESULTS The survival of mice improved in a dose-dependent fashion such that a significant difference
(p , 0.02) was found between the higher-dose pimobendan group (20 of 30 [66.7%]) and the
control group (11 of 30 [36.7%]). Histological scores for cellular infiltration (1.1 6 0.1 vs.
2.0 6 0.0, p , 0.001), intracardiac tumor necrosis factor (TNF)-a (18.2 6 1.8 vs. 35.8 6
4.2 pg/mg heart, p , 0.001) and interleukin (IL)-1b (9.3 6 1.2 vs. 26.6 6 7.1 pg/mg heart,
p , 0.01) were significantly lower in the mice given pimobendan versus those of the control
mice. Interleukin-6 levels (7.1 6 0.8 vs. 9.2 6 1.9 pg/mg heart) were also lower in the mice
treated with pimobendan. Furthermore, intracardiac NO production was significantly (p ,
0.001) less in the pimobendan group (0.165 6 0.004 nmol/mg heart) than in the control
group (0.291 6 0.051 nmol/mg heart), and intracardiac iNOS gene expression in the mice
given pimobendan was 74% lower than it was in the control animals (p , 0.01).
CONCLUSIONS These findings suggest that the beneficial effects of pimobendan in viral myocarditis are
partially mediated by the inhibition of both proinflammatory cytokine production and NO
synthesis by iNOS. (J Am Coll Cardiol 1999;33:1400–7) © 1999 by the American College
of Cardiology
Pimobendan, a phosphodiesterase (PDE) III inhibitor with
additional calcium-sensitizing properties, has recently been
confirmed to be effective in both acute and chronic heart
failure (1–3). Pimobendan is known to acutely improve
hemodynamics, increasing cardiac output and stroke volume
while reducing ventricular filling pressures and peripheral
resistance in patients suffering from severe congestive heart
failure (4). Despite the demonstration of favorable short-
term hemodynamic effects, recent multicenter trials of
several PDE III inhibitors have yielded disappointing re-
sults. Not only did the PDE III inhibitors amrinone,
milrinone and enoximone fail to demonstrate a significant
improvement in chronic heart failure, but they increased the
morbidity and mortality of patients with severe chronic
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heart failure (5–8). On the other hand, a multicenter trial
found that pimobendan chronically increased exercise dura-
tion, peak oxygen uptake and quality of life in patients with
severe congestive heart failure concomitantly treated with
digoxin, diuretics and angiotensin-converting enzyme in-
hibitors (9,10). Pimobendan and other PDE III inhibitors
seem to improve left ventricular performance by exerting
positively inotropic as well as vasodilating effects. However,
in comparison with other PDE III inhibitors, pimobendan
possesses the unique additional property of increasing the
affinity of cardiac contractile proteins for calcium which
adds to its inotropic activity (11,12). Thus far, the advantage
of pimobendan over the other PDE III inhibitors in
treatment of chronic heart failure has been attributed to this
calcium-sensitizing property.
Recent studies have revealed the roles played by various
cytokines in diverse cardiovascular disorders (13). The levels
of circulating tumor necrosis factor (TNF)-a, interleukin
(IL)-1b, IL-6 and other proinflammatory cytokines have
been found to be elevated in patients with myocarditis and
acute myocardial infarction (14–17). Furthermore, circulat-
ing TNF-alpha has been reported to be increased in patients
with chronic congestive heart failure, including in the
context of myocarditis, transplant rejection and dilated
cardiomyopathy (18–20).
In a murine model of encephalomyocarditis (EMC)
virus-induced myocarditis, the majority of mice die of
congestive heart failure due to severe myocarditis in the
acute stage (21). The severity in the course of the disease
appears to correlate with the degree of intracardiac produc-
tion of proinflammatory cytokines (22). Recent studies have
shown that several proinflammatory cytokines cause myo-
cardial contractile dysfunction and that their negative ino-
tropic effects may be mediated by nitric oxide (NO) (23,24).
We previously demonstrated that pimobendan strongly
inhibited the production of NO in cultured macrophages
stimulated by lipopolysaccharide (LPS) (25). Thus, in the
present study, we examined the effects of pimobendan in a
murine model of viral myocarditis induced by EMC virus in
relation to proinflammatory cytokine production and gene
expression of inducible nitric oxide synthase (iNOS) in the
heart.
METHODS
Viral infection. Four-week-old inbred male DBA/2 mice
were inoculated intraperitoneally with 0.1 mL of the M
(myocardiotrophic) variant of EMC virus diluted in Eagle’s
minimal essential medium to a concentration of 10 plaque-
forming units/mL. The day of virus inoculation was defined
as day 0 in all subsequent studies.
Drug preparation. Pimobendan (UD-CG 115 BS) was
supplied by Nippon Boehringer Ingelheim Co., Ltd., Ka-
wanishi, Japan. The drug was prepared as an oral suspension
in 0.25% methylcellulose solution in concentrations of
120 mg/mL and 12 mg/mL, and stored at 4°C.
Protocol 1—survival studies. Since, in this model, most
mice die of congestive heart failure within 14 days after
EMC virus inoculation (21), the survival was observed up to
14 days in this study. Pimobendan was administered in
doses of 0.1 mg/kg or 1 mg/kg daily for 14 days from the
day of EMC virus inoculation while control mice received
vehicles only. Thirty mice were randomly assigned to each
group.
Protocol 2— histochemical and pathological studies.
Since we had demonstrated in earlier studies that the
expression of intracardiac TNF-a messenger RNA
(mRNA) is maximal at seven days after virus inoculation in
the same murine model, the effects of pimobendan on the
production of TNF-a, other proinflammatory cytokines
(IL-1b and IL-6) and NO in the heart was examined on day
seven. On day 0 the mice were randomly assigned to receive
pimobendan in a dose of 1 mg/kg orally once daily (n 5 7
or 5) or vehicles only (n 5 5). The animals were sacrificed
by cervical dislocation under general anesthesia, seven days
after EMC virus inoculation. Following measurements of
body and heart weights, the hearts were divided into two
sections along their short axis at the midleft ventricular
level. The apical sections were used to determine intracar-
diac levels of cytokines and NO and the basal sections were
used for histological examination. For the measurements of
iNOS gene expression, the mice were randomly assigned to
receive pimobendan in a dose of 1 mg/kg orally once daily
(n 5 6) or vehicles only (n 5 5), and the hearts were
harvested in the same manner.
Histological examination. The hearts were fixed in 10%
formalin, embedded in paraffin, sectioned and stained with
hematoxylin and eosin. The extent of cellular infiltration
and myocardial necrosis was graded by two blinded observ-
ers and was scored as follows: 0 5 no lesions; 11 5 lesions
involving ,25% of the myocardium; 21 5 lesions involving
25% to 50% of the myocardium; 31 5 lesions involving
50% to 75% of the myocardium and 41 5 lesions involving
75% to 100% of the myocardium. The scores assigned by
the two observers were averaged.
Abbreviations and Acronyms
cAMP 5 cyclic adenosine monophosphate
EMC 5 encephalomyocarditis
iNOS 5 inducible nitric oxide synthase
IL 5 interleukin
LPS 5 lipopolysaccharide
mRNA 5 messenger RNA
NO 5 nitric oxide
PDE 5 phosphodiesterase
TNF 5 tumor necrosis factor
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Assay of intracardiac cytokines. Frozen sections of hearts
were mixed with 1.5 ml of PBS/0.05% NaN3 and homog-
enized with an ultrasonic liquid processor (ASTRASON™
Model XL2020, Misnox Inc., Farmingdale, New York).
Supernatants containing cytosolic protein were used to
detect the intracardiac cytokines with commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits
(TNF-a and IL-6: GENZYME Co., Cambridge, Massa-
chusetts; IL-1b: BioSource International Co., Camarillo,
California). The procedures were performed according to
the manufacturer’s recommendations. The detection limits
of TNF-a, IL-1b and IL-6 assays were 15 pg/mL, 7 pg/mL
and 5 pg/mL, respectively. Final results were expressed as
pg/mg of heart tissue.
Measurement of intracardiac NO production. Since
nitrite/nitrate are endproducts of NO, their production in
heart tissue was calculated from the levels of intracardiac
nitrite/nitrate measured by the Griess reaction (26,27).
Frozen sections of hearts were homogenized with 1.5 ml of
PBS as described above. After centrifugation, the superna-
tant was mixed with nitrate reductase (0.25 U/ml) and
incubated for 15 min at 37°C in the presence of 5 mM
NADPH. Fifty ml of the samples were incubated with 25 ml
of 1% sulfanilamide and 25 ml of 0.1% N-1-naphthyl-
ethylenediamine dihydrochloride in 5% phosphoric acid for
10 min. The absorbance at 540 nm (OD540) was measured
with a microplate reader (Multiskan BICHROMATIC,
Labsystems, Finland). Nitrite/nitrate concentrations were
calculated by comparison with OD540 of standard solutions
of sodium nitrite prepared in PBS. The final results were
expressed as nmol/mg of heart tissue.
Measurement of iNOS mRNA levels using the compet-
itive reverse-transcriptase polymerase chain reaction
(RT-PCR). Total RNA was extracted from the hearts
by the guanidinium thiocyanate-phenol-chloroform-
isoamylalcohol procedure. The RNA concentration was
measured spectrophotochemically. Five mg of total RNA
was subjected to first strand cDNA synthesis in a 40 mL
reaction mixture using murine leukemia virus reverse tran-
scriptase (Gibco BRL, Rockville, Maryland). The reaction
mixture was incubated at 37°C for 60 min, heated to 70°C
for 5 min to denature the reverse-transcriptase then cooled
on ice for 3 min. Sixty mL of water was added to each
sample.
Quantitative competitive PCR was developed as de-
scribed previously (28). Using a commercially available kit
(PCR MIMIC™ Construction Kit, CLONETECH Lab-
oratories Inc., Palo Alto, California), nonhomologous DNA
fragment with iNOS or glyceraldehyde-3-phosphate dehy-
drogenase (G3PDH) gene-specific primer templates was
constructed to be 148 or 184 nucleotides shorter than each
PCR product generated from native iNOS or G3PDH
cDNA, respectively. The primer sites for PCR were located
at nucleotides 2943 to 2967, and 3416 to 3440 of iNOS
cDNA and 51 to 75, and 816 to 840 of G3PDH cDNA.
The sense primer for iNOS was 59 CCC TTC CGA AGT
TTC TGG CAG CAG C 39 and the antisense primer was
59 GGC TGT CAG AGC CTC GTG GCT TTG G 39.
The sense primer for G3PDH was 59 TGA AGG TCG
GTG TGA ACG GAT TTG G 39 and the antisense
primer was 59 TCA GAT GCC TGC TTC ACC ACC
TTC T 39. One mL of the samples and 1 mL of two-fold
serial dilutions of the nonhomologous DNA fragment was
added to 23 mL of the PCR master mix, which contained
thermostable Taq polymerase (PERKIN ELMER Japan
Co., Tokyo, Japan), the gene-specific primers, dNTP, PCR
buffer and [a-32P]-dCTP. The two-fold serial dilutions of
constructed DNA, for example, were 1.0, 5.0 3 1021, 2.5 3
1021, 1.25 3 1021, 6.25 3 1022 and 3.125 3 1022
attomoles/mL (1 attomole 5 6 3 105 molecules). After
having heated the PCR mixture to 95°C for nine min to
activate thermostable Taq polymerase, PCR was performed
for 35 cycles, each consisting of denaturation at 94°C for
1 min, annealing at 60°C for 1 min and extension at 72°C
for 1 min. Ten mL of each PCR product was separated by
electrophoresis on a 5% polyacrylamide gel. The gels were
dried, autoradiographed with Fuji imaging plates (Fuji
Photo Film Co., Ltd., Tokyo, Japan) and analyzed with the
use of a Fujix BAS 2000 image analyzer (Fuji Photo Film
Co., Ltd.). The log of the ratio of iNOS or G3PDH target
radioactivity to the nonhomologous DNA fragment radio-
activity was plotted against the log of the number of the
nonhomologous DNA fragment molecules added to each
PCR reaction tube. The number of iNOS or G3PDH
cDNA was calculated from these plots. The values obtained
were expressed as attomoles/mg of total RNA. Each value of
iNOS cDNA was divided by that of the corresponding
G3PDH cDNA to be normalized. Finally, iNOS cDNA
levels, which were found to be equivalent to iNOS mRNA
levels, were expressed as percentages of G3PDH cDNA levels.
Statistical analysis. Survival was analyzed by the Kaplan-
Meier method. The x-square test was used for the final
survival rates. Student t test was used for cytokine levels,
nitrite/nitrate concentration levels, iNOS mRNA levels,
body weight, heart weight, heart weight to body weight
ratio and histological scores. Data are expressed as mean 6
SEM. Statistical significance was defined as p , 0.05.
RESULTS
Survival of the animals. Survival rates up to one week
showed little difference among the three groups of animals.
However, after day seven, the survival of mice treated with
pimobendan began to improve in a dose-dependent manner
(Fig. 1). The final survival rates on day 14 were 36.6% in the
control group, 53.3% in the pimobendan 0.1 mg/kg group
and 66.7% in the pimobendan 1 mg/kg group. The differ-
ence between the control group and the higher-dose pimo-
bendan group was statistically significant (p , 0.02). Thus,
pimobendan exerted beneficial effects on survival in this
murine model of EMC virus-induced myocarditis.
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Histopathology of the heart on day seven. Figure 2
illustrates the histopathological changes. Histopathological
scoring of the myocardium showed that the myocardial
cellular infiltration of the pimobendan 1 mg/kg group was
significantly reduced compared with the control group (p ,
0.001) while no statistically significant difference was found
in myocardial necrosis between the two groups (Table 1).
There were no significant differences in the heart weight to
body weight ratio between the control group and the
pimobendan 1 mg/kg group.
Intracardiac cytokines. Figure 3 shows the proinflamma-
tory cytokine protein levels in the whole heart homogenates
of the control group and the pimobendan 1 mg/kg group.
The intracardiac TNF-a level of the pimobendan 1 mg/kg
group (18.0 6 1.8 pg/mg heart, n 5 7) was significantly less
(p , 0.001) than that of the control group (35.8 6
4.2 pg/mg heart, n 5 5). The intracardiac IL-1b level of the
pimobendan 1 mg/kg group (9.3 6 1.2 pg/mg heart, n 5 7)
was also significantly less (p , 0.01) than that of the control
group (26.6 6 7.1 pg/mg heart, n 5 5). Although the
intracardiac IL-6 level in the pimobendan 1 mg/kg group
(7.1 6 0.8 pg/mg heart, n 5 7) was also less than that in the
control group (9.2 6 1.9 pg/mg heart, n 5 5), the difference
did not reach statistical significance (p 5 0.23).
Intracardiac NO production. The nitrite/nitrate concen-
trations in the hearts are shown in Figure 4. The intracar-
diac nitrite/nitrate concentrations in the control group (n 5
Figure 1. Effect of pimobendan on survival rate after EMC virus
inoculation. Beyond seven days, the survival rate was improved in
a dose-dependent manner. Treatment with pimobendan, 1 mg/
kg/day, significantly reduced mortality on day 14. * 5 p , 0.02
versus control. Each group consists of thirty mice.
Figure 2. Typical histopathologic changes found seven days after EMC virus inoculation. A and B: Heart from a control mouse. C and
D: Heart from a mouse treated with pimobendan 1 mg/kg. Extensive myocardial necrosis and cellular infiltration are found in the control
preparation. In the mouse treated with pimobendan, less myocardial cellular infiltration exists despite an equivalent amount of myocardial
necrosis. Hematoxylin and eosin stain—original magnification: A and C, 3 40, reduced by 65%; B and D, 3 200, reduced by 65%.
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5) and the pimobendan 1 mg/kg group (n 5 5) were
0.291 nmol/mg heart and 0.165 nmol/mg heart, respec-
tively. The intracardiac nitrite/nitrate concentration in the
pimobendan 1 mg/kg group was 43 percent lower than that
in the control group (p , 0.001).
Intracardiac iNOS gene expression. Figures 5A and 5B
are representative autoradiographs and plots of their densi-
tometrical results. PCR of the nonhomologous DNA frag-
ment with iNOS or G3PDH primer sites yielded a product
which was 148 or 184 nucleotides shorter than the product
derived from the native cDNA, respectively. The log of the
ratio of iNOS or G3PDH PCR product to the nonhomolo-
gous DNA fragment was plotted against the log of the
number of the nonhomologous DNA fragment molecules
added. The number of iNOS or G3PDH cDNA molecules
was obtained from the point where log (iNOS or G3PDH/
the nonhomologous DNA fragment) was equal to zero. The
percentages of iNOS mRNA levels against G3PDH
mRNA levels in the control group (n 5 5) and the
pimobendan 1 mg/kg group (n 5 6) were 59.5 6 11.6% and
15.4 6 4.4%, respectively. Thus, iNOS mRNA expression
in the pimobendan 1 mg/kg group was 74 percent lower
than that in the control group (p , 0.01, Fig. 5C).
DISCUSSION
Pimobendan is a PDE III inhibitor with additional
calcium-sensitizing properties. Recent trials have shown
that pimobendan is effective not only in acute but also in
chronic heart failure (3,4). Pimobendan improves hemody-
namics acutely, increasing cardiac output and stroke volume
and reducing ventricular filling pressures and peripheral
resistance in the failing heart (4) while chronically it increases
exercise duration, peak oxygen uptake and quality of life in
patients with severe chronic congestive heart failure (9,10). On
the other hand, several PDE III inhibitors other than pimo-
bendan and vesnarinone have been ineffective in the treatment
of chronic heart failure (5–8). A recent series of investigations
from our laboratory suggest that vesnarinone has immuno-
modulating properties and that it exerts its beneficial effect in
part via such properties. Indeed, vesnarinone lowered the
mortality both in a murine model of viral myocarditis (29) and
in a murine model of lethal endotoxemia (30).
We have previously studied the effects of PDE III
inhibitors, pimobendan, vesnarinone and amrinone on the
production of NO in cultured macrophages stimulated by
LPS (25). Pimobendan most strongly inhibited NO pro-
duction. Thus, in the present study, the effects of pimoben-
dan were investigated in a murine model of viral myocarditis
in the perspective of the production of proinflammatory
cytokines and iNOS gene expression in the heart. The doses
of pimobendan chosen for the experiments were
1 mg/kg/day and 0.1 mg/kg/day. A previous pharmacoki-
netic study in rats who had received a comparable oral dose
of pimobendan (31) suggests that its plasma and heart tissue
concentrations in the present study were close to the
concentrations found effective in our previous in vitro
studies (25,32). A dose of 1 mg/kg/day in the present study
is approximately ten times higher than the dose used in the
treatment of chronic heart failure in humans and thus, may
Figure 3. Effect of pimobendan on intracardiac production of TNF-a, IL-1b, and IL-6 measured on day seven after EMC virus
inoculation. The intracardiac TNF-a and IL-1b level in animals treated with pimobendan 1 mg/kg (n 5 7) were significantly lower than
those in the control group (n 5 5). * 5 p , 0.001 versus control. ** 5 p , 0.01 versus control. The intracardiac IL-6 level in the animals
treated with pimobendan 1 mg/kg was also less than in the control group, but the difference did not reach statistical significance.
Figure 4. Effect of pimobendan on intracardiac NO production.
The concentrations of nitrite/nitrate, stable endproducts of NO, in
the pimobendan 1 mg/kg group (n 5 5) were 43% lower than in
the control group (n 5 5). * 5 p , 0.01 versus control.
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seem to have been inappropriately high. However, on the
basis of body surface area, a dose of 1 mg/kg in mice is
equivalent to 0.08 mg/kg in humans, which is within the
range used clinically (33). Pimobendan improved the 14-day
survival of the animals in a dose-dependent manner. On
histological examination, myocardial cellular infiltration was
significantly reduced in mice given pimobendan in a dose of
1 mg/kg, and myocardial necrosis tended to be reduced.
Since both cytokines and NO are known to act mainly in an
autocrine or paracrine fashion, it is important to measure
their production at the level of a particular tissue. The
productions of TNF-a and IL-1b in the heart tissue were
reduced significantly in the pimobendan 1 mg/kg group,
and IL-6 showed a similar tendency. Furthermore, intra-
cardiac NO production and iNOS gene expression were also
significantly reduced by pimobendan.
Proinflammatory cytokines and NO in myocarditis and
the failing heart. Several clinical studies have described the
participation of proinflammatory cytokines in the pathogen-
esis of cardiac diseases. The levels of circulating proinflam-
matory cytokines such as TNF-a, IL-1 and IL-6 are
elevated in patients with myocarditis (14). It has also been
reported that levels of circulating IL-1, IL-6 and IL-8 are
elevated in patients with acute myocardial infarction (15–
17). A recent report from our laboratory has shown that, in
the same murine model of viral myocarditis, the intracardiac
expression of TNF-a, IL-1b, IFN-g and IL-2 genes was
increased at three days and reached maximal levels at seven
days after virus inoculation (22). The degree of their
expression correlated with the severity in the course of the
disease, suggesting that the overproduction of these proin-
flammatory cytokines by viral infection may aggravate the
disease. This is supported by the recent reports that the
overexpression of TNF-a in the heart caused severe myo-
carditis and cardiomegaly in transgenic mice (34) and that
IL-1b as well as TNF-a alone promoted coxsackie virus
B3-induced myocarditis in resistant mice (35). We previ-
ously showed that treatment with anti-TNF-a antibody had
improved both mortality and myocardial damage in the
acute stage of this myocarditis model (36), indicating that
the overproduction of TNF-a aggravates viral myocarditis.
Some experimental studies have indicated that these
proinflammatory cytokines may contribute to myocardial
contractile dysfunction. Infusion of TNF-a reversibly im-
paired left ventricular systolic and diastolic function in
conscious dogs (37). Tumor necrosis factor-a, IL-6 and
IL-2 inhibited contractility of isolated hamster papillary
muscles in a concentration-dependent and reversible man-
ner (23). Tumor necrosis factor-a exerted a direct negative
inotropic effect in both the human (38) and feline (39) left
ventricle and in isolated cardiac myocytes. Interleukin-1b
also depressed myocardial contractility in the isolated per-
fused rat heart (40). In addition to cardiac contractile
dysfunction, both TNF-a and IL-1b are known to cause
neonatal rat cardiac myocyte hypertrophy in vitro (41,42).
Overexpression of both IL-6 and IL-6 receptor also caused
ventricular myocardial hypertrophy in the transgenic mice
(43). Myocardial hypertrophy is considered to compensate
the failing heart at first but to be profoundly related to
ventricular remodeling leading to heart failure.
Although most of the signaling pathways of cardiac
contractile dysfunction related to proinflammatory cyto-
kines are still unclear, recent evidence suggests that the
direct negative inotropic effect of these cytokines may be
mediated by NO (23,44,45). Some experimental studies
have shown that IL-1b and IFN-g induce iNOS in both
adult rat ventricular myocytes (46) and intracardiac micro-
vascular endothelial cells (47), suggesting that the overpro-
duction of NO in myocytes and endothelial cells by proin-
flammatory cytokines may depress myocyte contractility in
an autocrine or paracrine fashion.
Inhibition of NO production in myocarditis. We have
shown here that both NO production and the expression of
iNOS gene in the heart were also significantly decreased by
pimobendan. We have previously reported the effect of NO
Figure 5. Quantification of iNOS mRNA in the hearts using
RT-PCR. A: Total RNA was extracted from the hearts in the
pimobendan 1 mg/kg group and the control group. Each PCR
product was separated by electrophoresis on a 5% polyacrylamide
gel. The gels were dried and autoradiographed. nh-DNA 5
nonhomologous DNA. B: The log of the ratio of iNOS or
G3PDH target radioactivity to the nh-DNA fragment radioactiv-
ity was plotted against the log of the number of the nh-DNA
fragment molecules added to each PCR reaction. The number of
iNOS or G3PDH cDNA molecules was obtained from the point
where log (iNOS or G3PDH/the nh-DNA fragment) was equal to
zero. C: The number of iNOS or G3PDH cDNA was expressed
as attomoles/mg of total RNA. The iNOS gene expression in the
pimobendan 1 mg/kg group was 74% lower than that of the
control group. * 5 p , 0.01 versus control.
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inhibition in the same model (48). Immunohistochemical
studies showed that macrophages and endothelium-like
cells stained positively for iNOS protein in the myocardium
of virus-inoculated mice but negatively in uninfected mice.
Furthermore, L-NMMA, an inhibitor of NOS, decreased
both cellular infiltration and myocardial necrosis signifi-
cantly. These results indicate a beneficial effect of NOS
inhibition in this model. This is supported by another recent
study in which the inhibition of NO synthesis by a relatively
specific iNOS inhibitor decreased myocardial inflammation
and necrosis in a rat autoimmune myocarditis (49). Oppo-
site observations have been reported of the promotion of
viral replication and myocardial damage (50) or of increased
mortality (51) in murine coxsackie virus B3-induced myo-
carditis by NOS inhibition. Although these reports appear
to contradict our results, it is likely that different degrees of
NO inhibition cause different responses: excessive inhibition
of NO may fail to suppress viral replication, resulting in
aggravation of myocarditis, whereas more moderate inhibition
of NO may salvage myocardial damage and contractile dys-
function. The degree of NO inhibition by pimobendan might
be appropriate to improve the disease in the present model.
Mechanism of action of pimobendan. The mechanism by
which pimobendan reduces the production of proinflamma-
tory cytokines and iNOS gene expression in the heart is
unclear. In our previous study, various PDE inhibitors
differentially inhibited the production of cytokines by hu-
man peripheral blood mononuclear cells stimulated by LPS
(31). Interestingly, most PDE inhibitors inhibited cytokine
production, though not 8 Br-cAMP. In addition, we
studied the effects of various PDE III inhibitors on the
production of NO in LPS-activated macrophages (25).
Although pimobendan strongly inhibited NO production, 8
Br-cAMP did not suppress, but increased, NO production.
Thus, the inhibitory effects of pimobendan on the produc-
tion of proinflammatory cytokines and iNOS gene expres-
sion cannot be explained by an increase in cAMP.
In the earlier in vitro study, pimobendan decreased the
production of TNF-a and IL-6 and increased IL-1b
production, whereas, in the present study, IL-1b production
and TNF-a were both significantly reduced by pimoben-
dan. Since different stimuli cause different patterns of
cytokine induction in vitro and in vivo, it is hypothesized
that there may be differences in the mode of cytokine
induction between the in vitro model and the present in vivo
model where viral infection is the main cause of the disease.
Conclusions. In conclusion, this study showed a therapeu-
tic effect of pimobendan in the acute stage of viral myocar-
ditis, mediated in part by inhibition of the inflammatory
response, of the production of proinflammatory cytokines
and of the synthesis of NO by iNOS. Pimobendan may be
of great value in the treatment not only of viral myocarditis
with heart failure but also of other cardiac diseases in which
the overproduction of proinflammatory cytokines and NO
play a significant pathogenetic role.
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